Intercommunication between the neuroendocrine and immune systems: Focus on myasthenia gravis

NeuroImmunoModulation

Volumn 18, Issue 5, 2011, Pages 320-327

  Mays, Jacqueline ^a   Butts, Cherié L ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Center for Drug Evaluation and Research   (United States)

Author keywords

Acetylcholine receptor; Autoimmunity; Immune system; Steroid hormones; Thymoma

Indexed keywords

ACETYLCHOLINE; AUTOANTIBODY; AZATHIOPRINE; CHOLINERGIC RECEPTOR; CYCLOSPORIN; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PYRIDOSTIGMINE; STEROID HORMONE; TACROLIMUS;

ABDOMINAL CRAMP; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; BRONCHUS SECRETION; CD4+ T LYMPHOCYTE; DIAPHORESIS; DIARRHEA; FEVER; HEADACHE; HUMAN; IMMUNE SYSTEM; MONOTHERAPY; MYASTHENIA GRAVIS; NAUSEA; NEUROENDOCRINE SYSTEM; NEUROMUSCULAR SYNAPSE; NOSE SECRETION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; SWEATING; THYMECTOMY; THYMOMA; VOMITING;

AGE OF ONSET; FEMALE; GONADAL STEROID HORMONES; HUMANS; IMMUNE SYSTEM; MALE; MYASTHENIA GRAVIS; NEUROSECRETORY SYSTEMS; RISK FACTORS; SEX FACTORS; THYMUS GLAND;

EID: 80053353514     PISSN: 10217401     EISSN: 14230216     Source Type: Journal    
DOI: 10.1159/000329491     Document Type: Review

References (56)

1. Carr AS, Cardwell CR, McCarron PO, Mc-Conville J: A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol 2010; 10: 46.
2. Meriggioli MN, Sanders DB: Autoimmune myasthenia gravis: Emerging clinical and biological heterogeneity. Lancet Neurol 2009; 8: 475-490.
3. Shelly S, Agmon-Levin N, Altman A, Shoenfeld Y: Thymoma and autoimmunity. Cell Mol Immunol 2011; 8: 199-202.
4. Strobel P, Chuang WY, Chuvpilo S, Zettl A, Katzenberger T, Kalbacher H, Rieckmann P, Nix W, Schalke B, Gold R, Muller-Hermelink HK, Peterson P, Marx A: Common cellular and diverse genetic basis of thymomaassociated myasthenia gravis: Role of MHC class II and AIRE genes and genetic polymorphisms. Ann NY Acad Sci 2008; 1132: 143-156. (Pubitemid 351841361)
5. Meriggioli MN: Myasthenia gravis with anti-acetylcholine receptor antibodies. Front Neurol Neurosci 2009; 26: 94-108.
6. Skeie GO, Romi F: Paraneoplastic myasthenia gravis: Immunological and clinical aspects. Eur J Neurol 2008; 15: 1029-1033.
7. Wen JC, Liu TC, Chen YH, Chen SF, Lin HC, Tsai WC: No increased risk of adverse pregnancy outcomes for women with myasthenia gravis: A nationwide population-based study. Eur J Neurol 2009; 16: 889-894.
8. Ferrero S, Esposito F, Biamonti M, Bentivoglio G, Ragni N: Myasthenia gravis during pregnancy. Expert Rev Neurother 2008; 8: 979-988. (Pubitemid 351872601)
9. Tellez-Zenteno JF, Hernandez-Ronquillo L, Salinas V, Estanol B, da Silva O: Myasthenia gravis and pregnancy: Clinical implications and neonatal outcome. BMC Musculoskelet Disord 2004; 5: 42.
10. Romi F, Skeie GO, Aarli JA, Gilhus NE: The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Arch Neurol 2000; 57: 1596-1600.
11. Bartoccioni E, Scuderi F, Augugliaro A, Chiatamone Ranieri S, Sauchelli D, Alboino P, Marino M, Evoli A: HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. Neurology 2009; 72: 195-197.
12. Deitiker PR, Oshima M, Smith RG, Mosier DR, Atassi MZ: Subtle differences in HLA DQ haplotype-associated presentation of AChR alpha-chain peptides may suffice to mediate myasthenia gravis. Autoimmunity 2006; 39: 277-288. (Pubitemid 44203504)
13. Vandiedonck C, Raffoux C, Eymard B, Tranchant C, Dulmet E, Krumeich S, Gajdos P, Garchon HJ: Association of HLA-A in autoimmune myasthenia gravis with thymoma. J Neuroimmunol 2009; 210: 120-123.
14. Giraud M, Taubert R, Vandiedonck C, Ke X, Levi-Strauss M, Pagani F, Baralle FE, Eymard B, Tranchant C, Gajdos P, Vincent A, Willcox N, Beeson D, Kyewski B, Garchon HJ: An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature 2007; 448: 934-937. (Pubitemid 47312776)
15. Abramson J, Giraud M, Benoist C, Mathis D: Aire's partners in the molecular control of immunological tolerance. Cell 2010; 140: 123-135.
16. Marx A, Hohenberger P, Hoffmann H, Pfannschmidt J, Schnabel P, Hofmann HS, Wiebe K, Schalke B, Nix W, Gold R, Willcox N, Peterson P, Strobel P: The autoimmune regulator AIRE in thymoma biology: Autoimmunity and beyond. J Thorac Oncol 2010; 5:S266-S272.
17. Whitacre CC: Sex differences in autoimmune disease. Nat Immunol 2001; 2: 777-780.
18. Djelmis J, Sostarko M, Mayer D, Ivanisevic M: Myasthenia gravis in pregnancy: Report on 69 cases. Eur J Obstet Gynecol Reprod Biol 2002; 104: 21-25. (Pubitemid 34786386)
19. Butts CL, Sternberg EM: Neuroendocrine factors alter host defense by modulating immune function. Cell Immunol 2008; 252: 7-15.
20. Li Y, Xiao B, Xiao L, Zhang N, Yang H: Myasthenia gravis accompanied by premature ovarian failure and aggravation by estrogen. Intern Med 2010; 49: 611-613.
21. Leker RR, Karni A, Brenner T, Weidenfeld J, Abramsky O: Effects of sex hormones on experimental autoimmune myasthenia gravis. Eur J Neurol 2000; 7: 203-206. (Pubitemid 32260569)
22. Polanczyk MJ, Hopke C, Vandenbark AA, Offner H: Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1). Int Immunol 2007; 19: 337-343. (Pubitemid 46344699)
23. Delpy L, Douin-Echinard V, Garidou L, Bruand C, Saoudi A, Guery JC: Estrogen enhances susceptibility to experimental autoimmune myasthenia gravis by promoting type 1-polarized immune responses. J Immunol 2005; 175: 5050-5057. (Pubitemid 41456388)
24. Nancy P, Berrih-Aknin S: Differential estrogen receptor expression in autoimmune myasthenia gravis. Endocrinology 2005; 146: 2345-2353. (Pubitemid 40577522)
25. Zhu J, Paul WE: CD4 T cells: Fates, functions, and faults. Blood 2008; 112: 1557-1569.
26. Protti MP, Manfredi AA, Straub C, Howard JF Jr, Conti-Tronconi BM: CD4+ T cell response to the human acetylcholine receptor alpha subunit in myasthenia gravis. A study with synthetic peptides. J Immunol 1990; 144: 1276-1281. (Pubitemid 20072895)
27. Moiola L, Galbiati F, Martino G, Amadio S, Brambilla E, Comi G, Vincent A, Grimaldi LM, Adorini L: IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease. Eur J Immunol 1998; 28: 2487-2497. (Pubitemid 28362723)
28. Liu R, Hao J, Dayao CS, Shi FD, Campagnolo DI: T-bet deficiency decreases susceptibility to experimental myasthenia gravis. Exp Neurol 2009; 220: 366-373.
29. Hirota K, Duarte JH, Veldhoen M, Hornsby E, Li Y, Cua DJ, Ahlfors H, Wilhelm C, Tolaini M, Menzel U, Garefalaki A, Potocnik AJ, Stockinger B: Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol 2011; 12: 255-263.
30. Protti MP, Manfredi AA, Straub C, Howard JF Jr, Conti-Tronconi BM: Immunodominant regions for T helper-cell sensitization on the human nicotinic receptor alpha subunit in myasthenia gravis. Proc Natl Acad Sci USA 1990; 87: 7792-7796.
31. Boonyapisit K, Kaminski HJ, Ruff RL: Disorders of neuromuscular junction ion channels. Am J Med 1999; 106: 97-113. (Pubitemid 29077145)
32. Hughes BW, Kusner LL, Kaminski HJ: Molecular architecture of the neuromuscular junction. Muscle Nerve 2006; 33: 445-461.
33. Mehndiratta MM, Pandey S, Kuntzer T: Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev 2011; 2:CD006986.
34. Angelini C: Diagnosis and management of autoimmune myasthenia gravis. Clin Drug Investig 2011; 31: 1-14.
35. Drachman DB: Myasthenia gravis. N Engl J Med 1994; 330: 1797-1810.
36. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD: Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976; 26: 1054-1059.
37. Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A: IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008; 131: 1940-1952. (Pubitemid 351957451)
38. Vincent A, Leite MI, Farrugia ME, Jacob S, Viegas S, Shiraishi H, Benveniste O, Morgan BP, Hilton-Jones D, Newsom-Davis J, Beeson D, Willcox N: Myasthenia gravis seronegative for acetylcholine receptor antibodies. Ann NY Acad Sci 2008; 1132: 84-92. (Pubitemid 351841363)
39. Ghazanfari N, Fernandez KJ, Murata Y, Morsch M, Ngo ST, Reddel SW, Noakes PG, Phillips WD: Muscle specific kinase: Organiser of synaptic membrane domains. Int J Biochem Cell Biol 2011; 43: 295-298.
40. Cole RN, Ghazanfari N, Ngo ST, Gervasio OL, Reddel SW, Phillips WD: Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice. J Physiol 2010; 588: 3217-3229.
41. Zielinski M: Management of myasthenic patients with thymoma. Thorac Surg Clin 2011; 21: 47-57, vi.
42. Okumura M, Inoue M, Kadota Y, Hayashi A, Tokunaga T, Kusu T, Sawabata N, Shiono H: Biological implications of thymectomy for myasthenia gravis. Surg Today 2010; 40: 102-107.
43. Cosi V, Citterio A, Lombardi M, Piccolo G, Romani A, Erbetta A: Effectiveness of steroid treatment in myasthenia gravis: A retrospective study. Acta Neurol Scand 1991; 84: 33-39.
44. Evoli A, Batocchi AP, Palmisani MT, Lo Monaco M, Tonali P: Long-term results of corticosteroid therapy in patients with myasthenia gravis. Eur Neurol 1992; 32: 37-43.
45. Pascuzzi RM, Coslett HB, Johns TR: Longterm corticosteroid treatment of myasthenia gravis: Report of 116 patients. Ann Neurol 1984; 15: 291-298. (Pubitemid 14164748)
46. Kuks JB, Djojoatmodjo S, Oosterhuis HJ: Azathioprine in myasthenia gravis: Observations in 41 patients and a review of literature. Neuromuscul Disord 1991; 1: 423-431.
47. Mantegazza R, Antozzi C, Peluchetti D, Sghirlanzoni A, Cornelio F: Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 1988; 235: 449-453. (Pubitemid 18262976)
48. Palace J, Newsom-Davis J, Lecky B: A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia gravis study group. Neurology 1998; 50: 1778-1783. (Pubitemid 28283251)
49. Minami N, Fujiki N, Doi S, Shima K, Niino M, Kikuchi S, Sasaki H: Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis. J Neurol Sci 2011; 300: 59-62.
50. Hart IK, Sharshar T, Sathasivam S: Immunosuppressant drugs for myasthenia gravis. J Neurol Neurosurg Psychiatry 2009; 80: 5-6.
51. Zhao CB, Zhang X, Zhang H, Hu XQ, Lu JH, Lu CZ, Xiao BG: Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis. Int Immunopharmacol 2011; 11: 519-524.
52. Chaudhuri A, Behan PO: Myasthenic crisis. QJM 2009; 102: 97-107.
53. Gilhus NE: Neuromuscular disease: Acute treatment for myasthenia gravis. Nat Rev Neurol 2011; 7: 132-134.
54. Mandawat A, Kaminski HJ, Cutter G, Katirji B, Alshekhlee A: Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol 2010; 68: 797-805.
55. Gajdos P, Chevret S, Toyka K: Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2008; CD002277.
56. Araujo LM, Chauvineau A, Zhu R, Diem S, Bourgeois EA, Levescot A, Huerre M, Gombert JM, Bayry J, Daeron M, Bruhns P, Kaveri SV, Herbelin A: Cutting edge: Intravenous Ig inhibits invariant NKT cell-mediated allergic airway inflammation through Fc γ RIIIA-dependent mechanisms. J Immunol 2011; 186: 3289-3293.